CA2895285C - Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same - Google Patents

Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same Download PDF

Info

Publication number
CA2895285C
CA2895285C CA2895285A CA2895285A CA2895285C CA 2895285 C CA2895285 C CA 2895285C CA 2895285 A CA2895285 A CA 2895285A CA 2895285 A CA2895285 A CA 2895285A CA 2895285 C CA2895285 C CA 2895285C
Authority
CA
Canada
Prior art keywords
disease
propyl
pharmaceutically acceptable
sulphate salt
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2895285A
Other languages
English (en)
French (fr)
Other versions
CA2895285A1 (en
Inventor
Stephane Burlet
Cecilia Estrella
Mathieu BARRIER
Patricia Melnyk
Nicolas Sergeant
Luc Buee
Philippe Verwaerde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALZPROTECT
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Original Assignee
ALZPROTECT
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Lille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALZPROTECT, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Lille filed Critical ALZPROTECT
Publication of CA2895285A1 publication Critical patent/CA2895285A1/en
Application granted granted Critical
Publication of CA2895285C publication Critical patent/CA2895285C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2895285A 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same Active CA2895285C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12306690 2012-12-27
EP12306690.4 2012-12-27
PCT/EP2013/078068 WO2014102339A1 (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Publications (2)

Publication Number Publication Date
CA2895285A1 CA2895285A1 (en) 2014-07-03
CA2895285C true CA2895285C (en) 2021-03-30

Family

ID=47501005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2895285A Active CA2895285C (en) 2012-12-27 2013-12-27 Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same

Country Status (23)

Country Link
US (3) US9562018B2 (https=)
EP (1) EP2938597B1 (https=)
JP (1) JP6384923B2 (https=)
KR (1) KR102115060B1 (https=)
CN (1) CN105008333B (https=)
AU (2) AU2013369288B2 (https=)
BR (1) BR112015015474B1 (https=)
CA (1) CA2895285C (https=)
DK (1) DK2938597T3 (https=)
ES (1) ES2605494T3 (https=)
HR (1) HRP20161612T2 (https=)
HU (1) HUE030930T2 (https=)
IL (1) IL239450B (https=)
LT (1) LT2938597T (https=)
MX (1) MX363367B (https=)
NZ (1) NZ708959A (https=)
PL (1) PL2938597T3 (https=)
PT (1) PT2938597T (https=)
RS (1) RS55511B1 (https=)
RU (1) RU2655454C2 (https=)
SI (1) SI2938597T1 (https=)
WO (1) WO2014102339A1 (https=)
ZA (1) ZA201504521B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2938597T (lt) 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas
HK1245272B (en) 2015-03-16 2019-09-27 Institut National De La Santé Et De La Recherche Médicale (Inserm) Novel 1,4-bis(3-aminopropyl)piperazine derivative and its use
TWI744300B (zh) * 2016-03-23 2021-11-01 里爾中央醫學中心 改良性熱處理的血小板顆粒裂解液在製備用於治療神經系統疾病的組合物的用途
JP2023543630A (ja) * 2020-10-01 2023-10-17 アルツプロテクト Ｎ－（３－（４－（３－（ジイソブチルアミノ）プロピル）ピペラジン－１－イル）プロピル）－１ｈ－ベンゾ［ｄ］イミダゾール－２－アミンのコハク酸塩、それらの調製及びそれらの使用
US20230364076A1 (en) * 2020-10-07 2023-11-16 Alzprotect Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders
CN118524838A (zh) 2021-12-20 2024-08-20 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺琥珀酸盐及其溶剂合物用于治疗运动神经元疾病和神经肌肉接头病症的用途
CN118946356A (zh) 2022-03-25 2024-11-12 雅尔兹普罗泰特公司 N-(3-(4-(3-(二异丁基氨基)丙基)哌嗪-1-基)丙基)-1H-苯并[d]咪唑-2-胺的盐及其溶剂化物用于治疗感觉神经元疾病的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
JP2001500162A (ja) * 1997-06-12 2001-01-09 トランジェーヌ、ソシエテ、アノニム 少なくとも１種の治療上有効な物質、特にポリヌクレオチド、を標的細胞に導入するための新規脂質複合体および遺伝子治療における使用
CN1325397A (zh) * 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
US20050020582A1 (en) * 2001-05-25 2005-01-27 Prusiner Stanley B Optically active compounds clearing malformed proteins
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
CA2509406C (en) * 2002-12-23 2012-07-03 Janssen Pharmaceutica N.V. Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
ATE524181T1 (de) * 2004-11-10 2011-09-15 Inst Nat Sante Rech Med Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
LT2938597T (lt) * 2012-12-27 2017-01-25 Alzprotect N-(3-(4-(3-(diizobutilamino)propil)piperazin-1-il)propil)-1h-benzo[d]imidazol-2-amino sulfatinės druskos, jų paruošimas ir panaudojimas

Also Published As

Publication number Publication date
AU2013369288A1 (en) 2015-07-02
RS55511B1 (sr) 2017-05-31
HUE030930T2 (hu) 2017-06-28
CN105008333A (zh) 2015-10-28
BR112015015474A2 (https=) 2017-08-15
DK2938597T3 (en) 2017-01-09
US10772884B2 (en) 2020-09-15
RU2655454C2 (ru) 2018-05-29
JP2016503813A (ja) 2016-02-08
US9562018B2 (en) 2017-02-07
HRP20161612T1 (hr) 2017-01-27
ES2605494T3 (es) 2017-03-14
RU2015130671A (ru) 2017-01-30
SI2938597T1 (sl) 2017-03-31
NZ708959A (en) 2019-11-29
EP2938597A1 (en) 2015-11-04
ZA201504521B (en) 2016-11-30
AU2018202218B2 (en) 2019-02-21
AU2013369288A8 (en) 2015-07-16
US20170151235A1 (en) 2017-06-01
IL239450B (en) 2018-06-28
JP6384923B2 (ja) 2018-09-05
LT2938597T (lt) 2017-01-25
US20160108003A1 (en) 2016-04-21
WO2014102339A1 (en) 2014-07-03
MX2015008502A (es) 2015-12-16
PT2938597T (pt) 2016-12-09
CA2895285A1 (en) 2014-07-03
MX363367B (es) 2019-03-20
AU2018202218A1 (en) 2018-04-26
CN105008333B (zh) 2018-02-09
KR20150105313A (ko) 2015-09-16
IL239450A0 (en) 2015-07-30
BR112015015474B1 (pt) 2022-04-19
AU2013369288B2 (en) 2018-02-22
US20190381036A1 (en) 2019-12-19
HK1215582A1 (en) 2016-09-02
US10537569B2 (en) 2020-01-21
KR102115060B1 (ko) 2020-05-25
EP2938597B1 (en) 2016-10-26
HRP20161612T2 (hr) 2017-02-24
PL2938597T3 (pl) 2017-03-31

Similar Documents

Publication Publication Date Title
US10772884B2 (en) Sulphate salts of N-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1H-benzo[d]imidazol-2-amine, preparation thereof and use of the same
ES2915833T3 (es) Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular
EP4353723A1 (en) Crystal form of tolebrutinib, preparation method therefor and use thereof
US10472353B2 (en) Salt and crystal forms of PLK-4 inhibitor
US20230331679A1 (en) Naphthalene monoimide compounds and methods thereof
AU2021353998B2 (en) Succinate salts of N-(3-(4-(3-(Diisobutylamino)Propyl)Piperazin-1-YL)Propyl)-1H-Benzo[D]Imidazol-2-Amine, Preparation Thereof And Use Of The Same
HK1215582B (en) Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same
US10150739B2 (en) Crystalline form of androgen receptor inhibitor and preparation method thereof
US9981912B2 (en) Cocrystal of lorcaserin, preparation methods, pharmaceutical compositions and uses thereof
US20250333381A1 (en) Solid state forms
US9056814B2 (en) Polymorphic form of a calcimimetic compound
US20240025868A1 (en) Phenothiazine compounds for the treatment of alzheimer's disease and other age-related and neurological diseases
HK40111001A (en) Crystal form of tolebrutinib, preparation method therefor and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181022

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251126

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251126